The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.
Fintel on MSN14h
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform RecommendationFintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...
Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
An analysis of a child health project reveals surprising factors in early-stage team success. When it comes to large research projects, strong leadership and experience may be a stronger predictor of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback